Loss of MTSS1 results in increased metastatic potential in pancreatic cancer
Metrics: PDF 897 views | HTML 1537 views | ?
Ann E. Zeleniak1,2, Wei Huang2,3, Mary K. Brinkman2,3, Melissa L. Fishel4,5,6, Reginald Hill2,3
1Integrated Biomedical Sciences Program, University of Notre Dame, South Bend, Indiana, USA
2Harper Cancer Research Institute, University of Notre Dame, South Bend, Indiana, USA
3Department of Biological Sciences, University of Notre Dame, South Bend, Indiana, USA
4Indiana University School of Medicine, Department of Pharmacology and Toxicology, Indianapolis, Indiana, USA
5Indiana University School of Medicine, Department of Pediatrics, Wells Center for Pediatric Research, Indianapolis, Indiana, USA
6Pancreatic Cancer Signature Center, Indianapolis, Indiana, USA
Reginald Hill, email: firstname.lastname@example.org
Keywords: pancreatic cancer, metastasis, MTSS1, inflammation, tumor microenvironment
Received: September 18, 2016 Accepted: January 19, 2017 Published: January 27, 2017
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of 7%. This dismal prognosis is largely due to the inability to diagnose the disease before metastasis occurs. Tumor cell dissemination occurs early in PDAC. While it is known that inflammation facilitates this process, the underlying mechanisms responsible for this progression have not been fully characterized. Here, we functionally test the role of metastasis suppressor 1 (MTSS1) in PDAC. Despite evidence showing that MTSS1 could be important for regulating metastasis in many different cancers, its function in PDAC has not been studied. Here, we show that loss of MTSS1 leads to increased invasion and migration in PDAC cell lines. Moreover, PDAC cells treated with cancer-associated fibroblast-conditioned media also have increased metastatic potential, which is augmented by loss of MTSS1. Finally, overexpression of MTSS1 in PDAC cell lines leads to a loss of migratory potential in vitro and an increase in overall survival in vivo. Collectively, our data provide insight into an important role for MTSS1 in suppressing tumor cell invasion and migration driven by the tumor microenvironment and suggest that therapeutic strategies aimed at increasing MTSS1 levels may effectively slow the development of metastatic lesions, increasing survival of patients with PDAC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.